Biocon inks licensing, supply pact with South Korea's Handok for chronic weight management product

Biocon signs exclusive licensing agreement with Handok for commercialisation of synthetic Liraglutide in South Korea, expanding portfolio to address weight management needs and tapping into a USD 47 million market opportunity. Biocon said the total addressable market opportunity of Liraglutide in South Korea is approximately USD 47 million as per the IQVIA MAT Q4 2023.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/wcN0ORa
via IFTTT